Katrin Lamszus

• Altered CD4 T cell response in oligometatastic non-small cell lung cancer brain metastasis
• Somatic mutations in HLA class genes and antigen presenting molecules in malignant glioma
• Identification and characterization of tertiary lymphoid structures in brain metastases
• Red blood cell-tumor cell interactions promote tumor cell progression
• Extracellular Vesicles Carrying Tenascin-C are Clinical Biomarkers and Improve Tumor-Derived DNA Analysis in Glioblastoma Patients
• Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics
• Cancer neuroscience and glioma: clinical implications
• EANO guideline on molecular testing of meningiomas for targeted therapy selection

Prof. Dr. med. Katrin Lamszus is a distinguished neuroscientist specializing in brain tumor biology. She leads the Laboratory for Brain Tumor Biology within the Department of Neurosurgery at the University Medical Center Hamburg-Eppendorf (UKE) in Germany. Her research focuses on the molecular and cellular mechanisms underlying primary and metastatic brain tumors, particularly glioblastoma and brain metastases.

Prof. Lamszus's work encompasses areas such as glioma stem-like cells, tumor heterogeneity, and the tumor microenvironment. She has contributed to studies on epidermal growth factor receptor (EGFR) amplification in glioblastoma stem-like cells, exploring how EGFR status affects tumor behavior and therapeutic response.

In addition to her research, Prof. Lamszus is involved in collaborative projects like the German Meningioma Consortium, where she investigates extracellular vesicles as biomarkers for meningioma subtypes and therapy response. german-meningioma-consortium.com

Her contributions to neuro-oncology are recognized through her role as an Associate Editor for journals such as Neuro-Oncology Advances. OUP Academic

For more information on Prof. Lamszus's work and publications, you can visit her profile on the University Medical Center Hamburg-Eppendorf website.

Mughal et al. performed transcriptome-wide gene expression profiling combined with spatial immune cell profiling to characterize the tumor immune microenvironment in 95 patients with BrM from different primary tumors. They found that BrM from lung cancer and malignant melanoma showed overall higher immune cell infiltration as compared to BrM from breast cancer. RNA sequencing-based immune cell deconvolution revealed gene expression signatures indicative of tertiary lymphoid structures (TLS) in subsets of BrM, mostly from lung cancer and melanoma. This finding was corroborated by multiplex immunofluorescence staining of immune cells in BrM tissue sections. Detection of TLS signatures was more common in treatment-naïve BrM and associated with prolonged survival after Brain metastases diagnosis in lung cancer patients. The findings highlight the cellular diversity of the tumor immune microenvironment in BrM of different cancer types and suggest a role of TLS formation for BrM patient outcome ¹⁾